Tight regulation of canonical Wnt/β-catenin signaling is critical for maintaining normal hematopoiesis and its deregulation contributes to leukemia development^[@R1]^. β-catenin, a central molecule in the canonical Wnt/β-catenin signaling pathway, acts as a nuclear transcriptional co-activator with the lymphoid enhancer factor/T cell factor (LEF/TCF) family to stimulate transcription of various target genes^[@R2]^. The intracellular level of β-catenin is controlled by a degradation complex consisting of Apc, Gsk-3β, Axin 1 and Ck-1^[@R2]^. We found that loss of *Apc* leads to bone marrow failure due to exhaustion of hematopoietic stem and progenitor cells in mice^[@R3]^. A marked decrease of Mac-1^+^Gr-1^+^ myeloid cells and rapid depletion of granulocyte-macrophage progenitors (GMPs), but not megakaryocyte-erythrocyte progenitors (MEPs) were observed in both *Apc*-null^[@R3]^ and transgenic mice with expression of stabilized β-catenin^[@R4],\ [@R5]^. However, whether this decrease of myeloid cells is due to a blockage of differentiation of GMPs or the depletion of GMPs in vivo or both have not been defined.

PU.1, a member of the Ets family of DNA-binding proteins, is encoded by the Sfpi1 gene and is an important transcriptional regulator that is required for the generation of early myeloid and lymphoid progenitors^[@R6]^. The PUER cells represent an experimentally manipulable cellular model system for analyzing molecular mechanisms that underlie macrophage differentiation in vitro. The PUER cells were originally derived from mouse PU.1^−/−^ myeloid progenitors with expression of a conditionally active PU.1 protein fused to the ligand binding domain of the estrogen receptor (PUER)^[@R7]^. Addition of 4-hydroxy-tamoxifen (4-OHT) leads to activation of PU.1 and differentiation of PUER cells. To test whether activation of Wnt/β-catenin signaling affects macrophage differentiation induced by PU.1 in PUER cells or not, we first expressed stabilized β-catenin mutant (β-catenin-S33Y)^[@R8]^ in PUER cells by retroviral vector Migr1, which co-expresses EGFP ([Supplementary Figure 1a](#SD1){ref-type="supplementary-material"}). The expression of β-catenin-S33Y was confirmed by Western blot ([Supplementary Figure 1b](#SD1){ref-type="supplementary-material"}). The PUER cells were derived from the original PUER line that was established in Dr. Singh's laboratory^[@R7]^. The current cell line underwent monocyte/macrophage differentiation with a low concentration of 4-OHT. Upon 4-OHT addition, PUER protein is induced in PUER cells and the cells undergo differentiation into Mac-1^+^/F4/80^+^ macrophages within 3--5 days ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). Of interest, induction of PU.1 expression in PUER cells with expression of the stabilized β-catenin resulted in a significantly low number of Mac1^+^/F4/80^+^ cells ([Figure. 1a](#F1){ref-type="fig"}). In the absence of 4-OHT, PUER cells with or without stabilized β-catenin displayed the morphology of myeloid progenitors with a large nucleus ([Figure 1b](#F1){ref-type="fig"}). After treatment of 4-OHT for 5 days, the vector-expressing cells increased in size with an extensive cytoplasm morphologically resembling macrophages. In contrast, the PUER cells with stabilized β-catenin had the same morphology as the cells without 4-OHT treatment ([Figure 1b](#F1){ref-type="fig"}). Taken together, these results suggest that stabilized β-catenin blocks PU.1-induced macrophage differentiation of PUER cells. APC negatively regulates the Wnt/β-catenin pathway by controlling the turnover of β-catenin^[@R3]^. We next explored the consequences of knockdown of the Apc gene on macrophage differentiation in PUER cells. Inhibition of Apc by Apc shRNA 1 or 2 against Apc in PUER cells led to stabilization of β-catenin ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). After induction of PU.1 for 3 days by 4-OHT treatment, PUER cells expressing Apc shRNA1 or 2 had a lower percentage of Mac1^+^/F4/80^+^ cells compared with the PUER cells expressing the control vector ([Figure 1c](#F1){ref-type="fig"}), indicating that activation of the Wnt/β-catenin pathway by Apc inhibition also represses PU.1-induced macrophage differentiation of PUER cells. In consistence, we found that stabilized β-catenin also blocked GM-CSF-driven macrophage differentiation of mouse primary bone marrow cells ([Figure 1d](#F1){ref-type="fig"}).

Next, we determined whether activation of Wnt/β-catenin inhibits differentiation of human U973 cells exposed to PMA. We found that either expression of stabilized β-catenin ([Supplementary Figure 4a](#SD1){ref-type="supplementary-material"}) or knockdown Apc expression ([Supplementary Figure 5a,b](#SD1){ref-type="supplementary-material"}) significantly reduced the frequency of Mac-1^+^ and CD14^+^ cells of U937 cells after exposed to PMA ([Supplementary Figure 4b](#SD1){ref-type="supplementary-material"}, [Figure 1e, f](#F1){ref-type="fig"}). Furthermore, stabilized β-catenin inhibits mRNA expression of CD14, Mac-1 and Csf1r genes induced by PMA in U937 cells, as determined by qRT-PCR ([Figure 1g](#F1){ref-type="fig"}). As shown in [Figure 1h](#F1){ref-type="fig"}, the morphological features associated with mature monocytes were observed in U937 cells expressing control vector but not β-cat-S33Y after PMA treatment for 48 hours. These regulates suggest that activation of Wnt/β-catenin signaling inhibits PMA-induced monocyte/macrophage differentiation of U937 cells. Together, our studies demonstrate a negative role of β-catenin overexpression in monocyte/macrophage differentiation.

To understand the mechanism by which β-catenin inhibits PU.1-mediated monocyte differentiation, we performed microarray analysis of gene expression profiling of PUER cells with expression of stabilized β-catenin or control vector before and after 24 h induction of PU.1 expression. As shown in [Supplementary Figure 6](#SD1){ref-type="supplementary-material"}, 505 genes were markedly up-regulated while 390 genes were significantly down-regulated by PU.1 gene expression (≥2 or ≤ 2fold, FDR\<0.01) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Induction of PU.1 expression in PUER cells with expression of stabilized β-catenin for 24 hours resulted in 505 genes up-regulated by PU.1 with 219 genes significantly inhibited by stabilized β-catenin. However, of 390 genes down-regulated by PU.1, 72 genes were up-regulated by stabilized β-catenin ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}, [Figure 2a](#F2){ref-type="fig"}), indicating that β-catenin significantly impairs PU.1-targeted gene transcription. Notably, more than 32% of PU.1-regulated genes were reversibly regulated by stabilized β-catenin, indicating that β-catenin overexpression antagonizes the function of PU.1 in myeloid progenitors.

Consistent with our microarray data, qRT-PCR analysis revealed that expression of a conditional version of PU.1 induced Egr2, Mmpl2, Emr1 and inhibited Gfi1 in PUER cells ([Figure 2b](#F2){ref-type="fig"}). Notably, stabilized β-catenin inhibited PU.1-induced Egr2, Mmpl2 and Emr1 and significantly increased Gfi1 expression. C/EBPα, which antagonizes PU.1-induced macrophage differentiation^[@R9]^, was also markedly up-regulated by stabilized β-catenin in PUER cells after induction of PU.1. It is likely that β-catenin overexpression antagonizes PU.1-contolled gene transcription, partially through up-regulating CEBPα and GFI1 expression.

Egr2 is a transcriptional master regulator that is regulated by PU.1 and cooperates with PU.1 in promoting monocyte-macrophage differentiation. It activates macrophage specific genes including Emr-1 and Mmpl2 and represses genes that promote neutrophil lineage differentiation, including Gfi1^[@R7]^. To determine whether stabilized β-catenin inhibited Egr2 expression in a human cell line during monocyte/macrophage differentiation, we expressed β-catenin-S33Y in U937 cells. EGR2 expression is determined by qRT-PCR before and after induction of monocyte/macrophage differentiation of U937 cells by PMA. Similarly, β-catenin-S33Y markedly suppressed PMA-induced EGR2 expression during U937 cell differentiation ([Figure 2c](#F2){ref-type="fig"}). Stabilized β-catenin significantly inhibited Egr2 expression in the absence of PU.1 gene expression, raising the possibility that β-catenin also directly regulates Egr2 expression. There are several predicted TCF4 binding sites identified on the promoter region of Erg2 ([Supplementary Figure 7](#SD1){ref-type="supplementary-material"}). Luciferase reporter showed that Egr2 promoter activity was repressed significantly with an increased amount of plasmids expressing stabilized β-catenin ([Figure 2d](#F2){ref-type="fig"}). Next, we performed chromatin immunoprecipitation (ChIP) assay followed by PCR. Our results revealed that both TCF4 and β-catenin binds directly to the predicted TCF4 binding sites in Egr2 promoter ([Figure 2e](#F2){ref-type="fig"}). To further determine whether down-regulation of Egr2 plays a critical role in mediating the inhibitory function of β-catenin in monocyte differentiation, we co-expressed Egr2 and β-catenin-S33Y in PUER and U937 cells. As shown in [Figure 2f](#F2){ref-type="fig"}, forced-expression of Egr2 reversed β-catenin-S33Y-induced inhibition of monocyte/macrophage differentiation of both PUER and U937 cells. In mouse primary BM cells, Egr2 expression was markedly increased at 12 hours and 24 hours after GM-CSF treatment. Notably, β-catenin-S33Y significantly blocked GM-CSF-induced Egr2 expression ([Figure 2g](#F2){ref-type="fig"}). Moreover, forced-expression of Egr2 reversed the inhibitory effect of stabilized β-catenin on monocyte/macrophage differentiation of primary BM cells ([Figure 2h](#F2){ref-type="fig"}). Together, stabilized β-catenin inhibits Egr2 expression in mouse primary BM cells, PUER and human U937 cells while forced expression of Egr2 released the blockage of monocyte-macrophage differentiation induced by stabilized β-catenin in these cells, suggesting an important role of Egr2 in mediating the negative effect of β-catenin overexpression in monocyte-macrophage differentiation.

β-catenin overexpression is frequently detected in AML samples and it is associated with an adverse prognosis^[@R10],\ [@R11]^. By analysis of a published set of microarray data from BM cells from 69 AML patients and 18 control healthy individuals^[@R12]^, we found that a group of AML patients (15 out of 69) had a markedly increased β-catenin expression as compared to healthy individuals (P=0.001) and the other AML patients (P=5.65E-10). Of interest, this group of AML patients with a high β-catenin expression displayed a reduced Egr2 expression in BM cells as compared to healthy individuals (P=0.0156) and the other AML patients (P=0.034) ([Figure 2i, j](#F2){ref-type="fig"}). These data suggest that an increased expression of β-catenin likely inhibits Egr2 expression in BM cells in AML patients.

In summary, we have shown that β-catenin overexpression induced blockage of monocyte-macrophage differentiation by inhibiting PU.1-targeted gene transcription including Egr2 expression in myeloid progenitor cells. A recent study showed that minimal PU.1 reduction induces myeloid-biased preleukemic stem cells and promotes subsequent transformation to AML in the context of Msh2-deficiency^[@R13]^. Therefore, compromised PU.1-targeted gene transcription induced by β-catenin overexpression, at least partially, may mediate a pathogenic role of β-catenin in myeloid leukemia.
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![Activated Wnt signaling blocks monocyte/macrophage differentiation in human and mouse progenitor cells\
(**a**) Histograms of flow cytometric analysis of PUER cells expressing Migr1-β-cat-S33Y or Migr1 vector after treatment with 4-OHT for 3 or 5 days. (**b**) May-Grünwald giemsa staining of PUER cells expressing Migr1-β-cat-S33Y or Migr1 vector after treatment with 5nM 4-OHT. The cells were stained with May-Grünwald giemsa. (**c**) Summary of flow cytometric analysis of F4/80^+^ (left panel) and Mac-1^+^ (right panel) PUER cells expressing shCon (control vector), APC shRNA\#1 or APC shRNA\#2 after treatment with 5 nM 4-OHT for 3 days. (**d**) Summary of flow cytometric analysis of percentage of F4/80^+^ cells and Mac-1^+^ cells in primary bone marrow (BM) cells expressing Migr1-β-cat-S33Y or Migr1 vector with treatment of 20ng/ml GM-CSF for 24 hours (vector-24h, β-cat-S33Y-24h) or vector-infected BM cells without addition of GM-CSF (vector-0h) in vitro. BM cells, isolated from the C57BL/6 mice, were infected with retrovirus expressing Migr1 or Migr1-β-cat-S33Y. Two days after infection, the cells were received GM-CSF treatment. (**e**) Summary of flow cytometric analysis of percentage of CD14^+^ and Mac-1^+^ in U937 cells expressing Migr1-β-cat-S33Y or Migr1 vector after treatment of 50 ng/ml PMA or vehicle for 48 hours. (**f**) Summary of flow cytometric analysis of percentage of CD14^+^ and Mac-1^+^ in U937 cells expressing ShCon (control), APCshRNA\#1 or APC shRNA\#2 after treatment of 50 ng/ml PMA or vehicle for 48 hours. (**g**) qRT-PCR analysis of the expression of Mac-1, CD14 and CSF1R in U937 cells expressing Migr1-β-cat-S33Y or Migr1 vector with or without PMA treatment. (**h**) May-Grünwald giemsa staining of U937 cells expressing control vector or β-cat-S33Y infected before and after treatment of PMA. All experiments were performed in triplicate. The results are representative of 3 independent experiments. \*, p\<0.05;\*\*, p\<0.01; \*\*\*, p\< 0.001.](nihms784088f1){#F1}

![Active β-catenin represses transcriptional programs induced by PU.1 in PUER cells and Egr2 partially rescues the blockage induced by stabilized β-catenin\
(**a**) Venn diagrams showing the PU.1-regulated genes that were down-regulated (right panel) or up-regulated (left panel) by stabilized β-catenin in PUER cells. (**b**) qRT-PCR analysis of expression of the selected genes in PUER cells expressing GFP (Migr1) control vector or Migr1-β-cat-S33Y (right panel) with or without induction of PU.1. Gene expression was normalized initially to Hprt expression. (**c**) Active β-catenin inhibits *Egr2* expression in U937 cells. Egr2 expression was determined by qRT-PCR in U937 cells expressing β-cat-S33Y or control vector. The U937 cells were cultured with PMA for 12 hours before analysis. (**d**) Egr2 promoter is downregulated by β-catenin. The luciferase reporter plasmid containing Egr2 promoter, control plasmids and plasmids expressing stabilized β-catenin were co-transfected into 293T cells. The amount of β-catenin plasmids were increased gradually with gradually reduced amount of control plasmids to keep constant amount of plasmids added in each sample. Experiments were repeated for three times. (**e**) β-catenin and TCf4 directly binds the Egr2 promoter. β-catenin, TCF4 antibodies and IgG were used to perform the ChIP assay and PCR products were run on 2% gel. Specific DNA bands were amplified by primers of Site1 and Site2 from DNA immunoprecipitated by β-catenin or TCF4 antibodies but not control IgG. Experiments were repeated for two times. (**f**) Summary data of flow cytometric analysis of PUER cells and U937 cells. The percentage of F4/80-positive cells was determined in PUER cells expressing control vector, β-catenin or β-catenin and Egr2 after treatment of 5 nM 4-OHT for 24 hours (left panel). The percentage of CD14-positive cells in was determined in U937 cells expressing control vector, β-catenin or β-catenin and Egr2 after treatment of 50 ng/ml PMA for 48 hours (right panel). (**g**) β-catenin inhibits Egr2 expression in BM cells. Egr2 expression was determined by qRT-PCR in BM cells expressing vector or β-catenin-S33Y before (0h) and after treatment of 20ng GM-CSF for 12 or 24 hours (12h, 24h). BM cells were infected with retrovirus expressing MSCV-neo vector or MSCV-neo-β-catenin-S33Y and cultured in medium with neomycin for 4 days before GM-CSF treatment. (**h**) Summary of flow cytometric analysis of percentage of F4/80^+^ cells in BM cells expressing MSCV-neo and Migr1, or Migr1-β-cat-S33Y or MSCV-neo-Egr2 and Migr1-β-cat-S33Y with treatment of 20ng/ml GM-CSF for 24 hours in vitro. (**I, J**) Egr2 is downregulated in BM cells from AML patients with β-catenin overexpression as compared to BM cells from healthy individuals. The signal intensities of Egr2 (probe ID: ILMN_1743199) and β-catenin (probe ID: ILMN_1808436) (probe ID: ILMN_2392043) from published microarray dataset (Series GSE34823) of BM mononuclear cells from 15 AML samples with top-level expression of β-catenin, 54 other AML samples and 18 control samples from healthy individuals were analyzed. The experiments were performed in triplicate. Data are representative of 2--3 independent experiments. \*, p\<0.05;\*\*, p\<0.01; \*\*\*, p\< 0.001.](nihms784088f2){#F2}

[^1]: These authors contributed equally to this work.
